OVARIAN CANCER

(1), ovarian cancer-chemotherapy drug commonly used drug <BR> melphalan (PAM) 0.2 ^ / ㎏ d, oral, 4 ~ for a course on the 5th, rest four to six weeks after duplication. Thiotepa (161-169) 10 ^ / times, intramuscular or intravenous injection, used five times, every other day to once a total of 300 ~ 500 days for an induction course. 6 to 8 weeks under the condition repeat. Cyclophosphamide (CTX) 50 ~ 100 ^ / day, oral, 7 ~ 10 Tianyi treatment, two weeks after duplication. Or 400 ^ / day, intravenous, oral to four days. Adriamycin (ADM) 50 ~ 70 ^ / ㎡, intravenous injection. Every three weeks.
(2), and malignant ovarian tumor joint chemical treatment of ovarian cancer chemotherapy are better response. In recent years the chemical treatment of tumors faster progress in the treatment of ovarian cancer Habitat has an important place to improve the treatment of ovarian cancer play a positive role as a surgical adjuvant therapy, commonly used in the preoperative, intraoperative and postoperative, but often require a longer period of intermittent medication, and the human body toxicity also sometimes larger. In most cases, it is difficult to ovarian cancer surgery primary tumor and metastasis consider chemical treatment based treatment.

Tags: body, cancer, cases, chemotherapy, days, drug, eat, injection, intravenous, malignant, metastasis, ovarian, positive, response, surgery, surgical, therapy, time, toxicity, treatment, tumor, tumors

Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect certainly, but in some patients because of poor health and not systemic tolerance of the boil, and in some patients for fear of adverse reactions of chemotherapy automatically abandon further treatment, which greatly affects the quality of life and survival rate , an increase of ovarian cancer recurrence possible. The TCM adjuvant treatment of patients with chemotherapy can improve and the tolerance level of immunity and, therefore, Chinese medicine treatment of ovarian cancer has been more and more attention.

Tags: age, bleeding, cancer, cause, chemotherapy, cisplatin, clinical, drug, drugs, eat, ert, gene, injection, intravenous, knowledge, life, ovarian, patients, poor, prognosis, quality, rate, second, surgery, survival, symptoms, therapy, time, treatment, tumor, tumors

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

I. Overview

With the aging of the global trend of development, improve the economic status of women, more and more women start hormone replacement therapy (Hormone Replacement Therapy, HRT), to improve access to after menopause due to the decrease in the level of sex hormones related to various diseases. Clear evidence that: postmenopausal women with age, the incidence of coronary heart disease increased by about four times the fracture due to osteoporosis by 20%, died of complications due to pelvic fracture rate of 30%, after the 65-year-old Alzheimer's incidence rate increase every year <BR> and Application HRT can peer groups coronary heart disease risk 50% Alzheimer's risk reduced three times, especially worth mentioning is significantly reduced the incidence of rectal cancer. Long-term use of HRT cancer risk reduced year by year. HRT can also greatly improve the menopause, postmenopausal women with disease or ovarian surgery, radiotherapy in patients with a series of artificial menopause syndrome.

Tags: age, benign, blood, body, brca1, breast, cancer, carcinoma, care, cases, cause, cell, cells, clinical, cyst, cystic, diagnosis, diet, drug, early, eat, ert, estrogen, family, fat, gene, grams, group, groups, growth, gynecological, history, hrt, incidence, increased, injection, intravenous, life, lymph, malignant, metastasis, method, mutation, node, ovarian, patients, pelvic, positive, protein, quality, radiotherapy, rate, reduce, residual, risk, screening, second, study, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, tumors, usually, uterine, women

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment

[Summary]

Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the uterus, which ranked third. But ovarian cancer death, accounts of the first gynecologic tumors, right pose a serious threat to women's lives. Because ovarian embryonic development, organization anatomy and endocrine function more complicated, it may be suffering from benign tumors or malignant. Because of early ovarian cancer in asymptomatic, and the identification of its type benign and malignant very difficult, ovarian carcinoma laparotomy in ovarian tumor confined to only 30%, most have spread to the uterus, bilateral annex, the omentum and pelvic organs, both in the diagnosis of ovarian cancer and governance the treatment is a major problem indeed. Over the years experts on the pathological form of ovarian cancer, the development of clinical and treatment programs for many of accumulated a lot of experience, so far, statistics on domestic and foreign clinical data, the five-year survival rate of only 25% to 30%.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, cancer, carcinoma, care, cases, cause, cell, cells, chemotherapy, clinical, cyst, cystic, days, diagnosis, dose, drug, drugs, early, eat, ert, estrogen, examination, exploration, gene, grams, growth, gynecological, history, incidence, increased, injection, intraperitoneal, intravenous, irradiation, life, lymph, malignant, mass, metastasis, method, node, oppression, ovarian, ovary, pain, patients, pelvic, poor, prognosis, protein, radiation, radiotherapy, rate, reduce, resection, residual, screening, staging, surface, surgery, surgical, survival, symptoms, syndrome, therapy, time, toxicity, treatment, tumor, tumors, uterine, women

The clinical diagnosis of ovarian tumors should meet four requirements:
(1) whether ovarian tumor;
(2) what ovarian tumor;
(3) Whether complications;
(4), Mr lateral growth.

Regarding the diagnosis of ovarian tumors
Ovarian cancer diagnosis often tumor size, different characters with ease and the difference, when asked in detail about history not only to genital mutilation, and the situation required attention to the whole body and other vital organs of the relevant history; Combined with clinical manifestations and physical examination, in addition to the characteristics of tumor itself, the whole body should be aware of the situation yet , it not only gynecological examination, and whole body check, especially abdominal inspection also very important. When necessary, with other diagnostic methods, such as pregnancy tests, the whole digestive tract X-ray fluoroscopy, hysterosalpingography, intravenous pyelography, diagnostic ultrasound or CT, MRI, and the special circumstances of individual abdominal puncture, laparoscopy, laparotomy, combined with the history after a comprehensive analysis in order to get a correct diagnosis.

Tags: abdominal, age, annex, anti, benign, body, cancer, carcinoma, cases, clinical, cyst, cystic, cysts, diagnosis, eat, ert, examination, gene, growth, gynecological, history, intravenous, malignant, mass, method, ovarian, pain, patients, physical, skin, surface, symptoms, treatment, tumor, tumors, uterine

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women